XORTX Therapeutics (XRTX) Gains from Equity Investments (2021 - 2026)
XORTX Therapeutics' (XRTX) quarterly Gains from Equity Investments came in at -$7000.0 in Q1 2026, up 97.15% YoY from -$3550.5 in Q1 2025, and up 92.47% on a QoQ basis from -$93000.0 in Q4 2025.
XORTX Therapeutics (XRTX) Gains from Equity Investments (2021 - 2026) Analysis & Trends
XORTX Therapeutics (XRTX) has 5 years of Gains from Equity Investments data on file, last reported at -$7000.0 in Q1 2026.
- Quarterly Gains from Equity Investments rose 97.15% year-over-year to -$7000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$325000.0 (up 65.27% YoY) and the FY2025 annual result came in at -$564000.0, down 154.49% from the prior year.
- Gains from Equity Investments grew to -$7000.0 in Q1 2026, from -$93000.0 in the prior quarter.
- In the past five years, Gains from Equity Investments ranged from a high of $1.7 million in Q1 2024 to a low of -$1.6 million in Q2 2024.
- A 4-year average of -$225671.7 and a median of -$244000.0 in 2024 frame the typical range for Gains from Equity Investments.
- Annual changes were most pronounced in 2022 — Gains from Equity Investments sank 131.32% — and 2026, when it jumped 97.15%.
- Tracing XRTX's Gains from Equity Investments over 4 years: stood at -$1.6 million in 2022, then jumped by 175.94% to $1.2 million in 2024, then tumbled by 107.75% to -$93000.0 in 2025, then surged by 92.47% to -$7000.0 in 2026.
- The last three Gains from Equity Investments figures came in at -$7000.0 (Q1 2026), -$93000.0 (Q4 2025), and -$76000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | XORTX Therapeutics | 2.84 Mn | 2.84 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -7,000.00 |
| Mar 31, 2026 | -7,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Dec 31, 2025 | -93,000.00 |
| Sep 30, 2025 | -76,000.00 |
| Sep 30, 2025 | -76,000.00 |
| Jun 30, 2025 | -149,000.00 |
| Jun 30, 2025 | -149,000.00 |
| Mar 31, 2025 | -246,000.00 |
| Mar 31, 2025 | -246,000.00 |
| Dec 31, 2024 | 1.20 Mn |
| Dec 31, 2024 | 1.20 Mn |
| Sep 30, 2024 | -244,000.00 |
| Sep 30, 2024 | -244,000.00 |
| Jun 30, 2024 | -1.65 Mn |
| Jun 30, 2024 | -1.65 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Mar 31, 2024 | 1.72 Mn |
| Dec 31, 2022 | -1.58 Mn |
| Dec 31, 2022 | -1.58 Mn |